Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors

Sao Paulo Medical Journal

Volumn 127, Issue 5, 2009, Pages 288-294

  Valentin, Mev Dominguez ^a,b   Canalle, Renata ^a,c   De Queiroz, Rosane Paula ^a   Tone, Luiz Gonzaga ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

^c FEDERAL UNIVERSITY OF PIAUÍ   (Brazil)

Author keywords

Blotting, western; Brain neoplasms; Cyclin dependent kinase inhibitor p21; Polymorphism, genetic; Polymorphism, restriction fragment length

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A;

3' UNTRANSLATED REGION; ADULT; ARTICLE; ASTROCYTOMA; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; EPENDYMOMA; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MALE; MEDULLOBLASTOMA; PREVALENCE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 77349123743     PISSN: 15163180     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-31802009000500008     Document Type: Article

References (29)

1. Baldwin RT, Preston-Martin S. Epidemiology of brain tumors in childhood - a review. Toxicol Appl Pharmacol. 2004;199(2):118-31.
2. Wechsler-Reya R, Scott MP. The developmental biology of brain tumors. Annu Rev Neurosci. 2001;24:385-428.
3. Nakatani F, Tanaka K, Sakimura R, et al. Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem. 2003;278(17):15105-15.
4. Kokunai T, Tamaki N. Relationship between expression of p21WAF1/CIP1 and radioresistance in human gliomas. Jpn J Cancer Res. 1999;90(6):638-46.
5. Milner BJ, Hosking L, Sun S, Haites NE, Foulkes WD. Polymorphisms in P21CIP1/WAF1 are not correlated with TP53 status in sporadic ovarian tumours. Eur J Cancer. 1996;32A(13):2360-3.
6. Viale G, Pellegrini C, Mazzarol G, Maisonneuve P, Silverman ML, Bosari S. p21WAF1/CIP1 expression in colorectal carcinoma correlates with advanced disease stage and p53 mutations. J Pathol. 1999;187(3):302-7.
7. Cheng L, Lloyd RV, Weaver AL, et al. The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin Cancer Res. 2000;6(5):1896-9.
8. Jahnson S, Karlsson MG. Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma. Cancer. 2000;89(3):619-29.
9. Shih CM, Lin PT, Wang HC, Huang WC, Wang YC. Lack of evidence of association of p21WAF1/CIP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan. Jpn J Cancer Res. 2000;91(1):9-15.
10. Facher EA, Becich, MJ, Deka A, Law JC. Association between human cancer and two polymorphisms occurring together in the p21Waf1/Cip1 cyclin-dependent kinase inhibitor gene. Cancer. 1997;79(12):2424-9.
11. Nadal A, Jares P, Cazorla M, et al. p21WAF1/Cip1 expression is associated with cell differentiation but not with p53 mutations in squamous cell carcinomas of the larynx. J Pathol. 1997;183(2):156-63.
12. Liao WM, Zhang CL, Li FB, Zeng BF, Zeng YX. p21WAF1/CIP1 gene DNA sequencing and its expression in human osteosarcoma. Chin Med J (Engl). 2004;117(6):936-40.
13. Harada K, Ogden GR. An overview of the cell cycle arrest protein, p21(WAF1). Oral Oncol. 2000;36(1):3-7.
14. Marchetti A, Doglioni C, Barbareschi M, et al. p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene. 1996;12(6):1319-24.
15. Souza RJSP. Estudo das alterações genéticas envolvendo o gene p21 (WAF1/CIP1/CDNK1) em meduloblastomas, ependimomas e ependimoblastomas, em menores de 18 anos. [dissertation]. Ribeirão Preto;. Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo;- 2003.
16. Mousses S, Ozçelik H, Lee PD, Malkin D, Bull SB, Andrulis IL. Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum Mol Genet. 1995;4(6):1089-92.
17. Law JC, Deka A. Identification of a PstI polymorphism in the p21Cip1/Waf1 cyclin-dependent kinase inhibitor gene. Hum Genet. 1995;95(4):459-60.
18. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227(5259):680-5.
19. Agresti A. Modelling patterns of agreement and disagreement. Stat Methods Med Res. 1992;1(2):201-18.
20. Kleinbaum J, Shamoon H. Selective counterregulatory hormone responses after oral glucose in man. J Clin Endocrinol Metab. 1982;55(4):787-90.
21. Koopmann J, Maintz D, Schild S, et al. Multiple polymorphisms, but no mutations, in the WAF1/CIP1 gene in human brain tumours. Br J Cancer. 1995;72(5):1230-3.
22. Chedid M, Michieli P, Lengel C, Huppi K, Givol D. A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. Oncogene. 1994;9(10):3021-4.
23. Birgander R, Själander A, Saha N, Spitsyn V, Beckman L, Beckman G. The codon 31 polymorphism of the p53-inducible gene p21 shows distinct differences between major ethnic groups. Hum Hered. 1996;46(3):148-54.
24. Rodrigues FC, Kawasaki-Oyama RS, Fo JF, et al. Analysis of CDKN1A polymorphisms: markers of cancer susceptibility? Cancer Genet Cytogenet. 2003;142(2):92-8.
25. Rastinejad F, Blau HM. Genetic complementation reveals a novel regulatory role for 3' untranslated regions in growth and differentiation. Cell. 1993;72(6):903-17.
26. Konishi R, Sakatani S, Kiyokane K, Suzuki K. Polymorphisms of p21 cyclin-dependent kinase inhibitor and malignant skin tumors. J Dermatol Sci. 2000;24(3):177-83.
27. Shiohara M, el-Deiry WS, Wada M, et al. Absence of WAF1 mutations in a variety of human malignancies. Blood. 1994:84(11):3781-4.
28. Jung JM, Bruner JM, Ruan S, et al. Increased levels of p21WAF1/Cip1 in human brain tumors. Oncogene. 1995;11(10):2021-8.
29. Rajaraman P, Wang SS, Rothman N, et al. Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol Biomarkers Prev. 2007;16(8):1655-61.